| DB ID | MyCo_6321 |
| Title | Interplay between Humoral and CLA+ T Cell Response against Candida albicans in Psoriasis |
| Year | 2021 |
| PMID | 33546306 |
| Fungal Diseases involved | Candida albicans infection |
| Associated Medical Condition | Psoriasis |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Comité Ético de Investigación Clinica (CEIC) del Hospital del mar (nº2016/6614/I on 20 January 2017). |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Plasma |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | Anti-CA IgA |
| Biomarker Full Name | Anti-Candida albicans Immunoglobulin A |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Bioinformatics analysis |
| Analysis Method | Proteomics Approach |
| ELISA kits | ELISA Kit (BD Bioscience, Franklin Lakes, NJ, USA) |
| Assay Data | None |
| Validation Techniques used | ELISA, Proteomics Approach |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
